We classified NF1 mutations as a MAPK alteration, consistent with recent breast cancer literature, and because of the greater interest in targeting NF1 germline-mutant tumors with MAPK targeting NF1. 27,28 MAPK pathway is involved in many cellular processes including cell proliferation, differentiation, and transcriptional regulation. Here, NF1 is linked to breast cancer.